A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)
Phase 1
- Conditions
- Immune ThrombocytopeniaMedDRA version: 23.0Level: PTClassification code: 10083842Term: Immune thrombocytopenia Class: 100000004851Therapeutic area: Diseases [C] - Hemic and Lymphatic Diseases [C15]
- Registration Number
- CTIS2023-509397-39-00
- Lead Sponsor
- Principia Biopharma Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 83
Inclusion Criteria
Male or female patients, aged 18 to 80 years old, Immune-related ITP (both primary and secondary)
Exclusion Criteria
Pregnant or lactating women, Current drug or alcohol abuse, History of solid organ transplant, Positive screening for HIV, hepatitis B, or hepatitis C
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method